ImmunoCellular Therapeutics to Present Today Data From Phase I Clinical Trial of ICT-107 at Annual Meeting of Congress of Neurological Surgeons

Company to Host Conference Call to Discuss Results on
Tuesday, October 27that 11a.m. eastern
time

LOS ANGELES--(BUSINESS WIRE)--Oct 26, 2009 - ImmunoCellular
Therapeutics, Ltd. (OTCBB: IMUC), a clinical-stage biotechnology
company that is developing immune-based therapies for the treatment
of brain and other cancers, today announced that it will be
presenting today, at the Annual Meeting of the Congress of
Neurological Surgeons in New Orleans, Louisiana at 3:15pm central
time, data from its Phase I clinical trial investigating the role
that its ICT-107 vaccine may play in increasing patient survival
and inhibiting tumor progression in patients with glioblastoma, the
most common and most aggressive type of primary brain tumor.

The company will hold a conference call on Tuesday, October
27th at 11 a.m. eastern time to discuss the data
presented at the conference. Interested parties may access the call
by dialing (877) 407-0778 domestically, or (201) 689-8565
internationally. A replay of the call will be available until
November 10, 2009, and can be accessed by dialing (877) 660-6853
domestically, or (201)-612-7415 for international audiences, and
using account # 286 and Conference ID #: 336119.

The call will also be available via a simultaneous live webcast,
and can be accessed by visiting
http://iq-vcall.incommsolutions.com and using InComm IQueue
Conference Number: 00336119. Please note that webcast audiences
must use Internet Explorer to access the broadcast.

About ImmunoCellular Therapeutics, Ltd.

IMUC is a Los Angeles-based clinical-stage company that is
developing immune-based therapies for the treatment of brain and
other cancers. The company's “off the shelf”
therapeutic vaccine product candidate targeting cancer stem cells
for multiple cancer indications is targeted by IMUC to enter
clinical trials for glioblastoma during the first quarter of 2010.
IMUC also recently completed a Phase I trial of its dendritic
cell-based clinical product candidate for glioblastoma. IMUC has
entered into a research and license option deal with the Roche
Group for one of its monoclonal antibodies for the diagnosis and
treatment of ovarian cancer and multiple myeloma, that provides for
potential licensing and milestone payments of $32MM and royalties
if the Roche Group exercises its option and commercializes this
antibody technology for multiple indications. IMUC is in
pre-clinical development of another monoclonal antibody product
candidate for the treatment of small cell lung cancer and
pancreatic cancer, and is also evaluating its platform technology
for monoclonal antibody discovery using differential immunization
for diagnosing and treating multiple types of cancer. To learn more
about IMUC, please visit
www.imuc.com.

About the CNS

The Congress of Neurological Surgeons, a leader in education and
innovation, is dedicated to advancing neurosurgery by providing
members with the educational and career development opportunities
they need to become leaders and innovators in the field. The
Congress of Neurological Surgeons exists to enhance health and
improve lives worldwide through the advancement of education and
scientific exchange.

The Congress of Neurological Surgeons serves to promote health
by advancing neurosurgery worldwide through innovation and
excellence in education. The Congress of Neurological Surgeons
provides global leadership in neurosurgery by inspiring and
facilitating scientific discovery and its translation into clinical
practice. The Congress of Neurological Surgeons maintains the
vitality of the profession through volunteer efforts of its members
and the development of leadership in service to the public, to
colleagues in other disciplines, and to neurosurgeons throughout
the world in all stages of their professional lives.

Forward-Looking Statements

This press release contains certain forward-looking statements
that are subject to a number of risks and uncertainties, including
without limitation, the risks associated with the potential
inability to obtain licenses from third parties that will be needed
to commercialize ICT-107 in many major commercial territories; the
potential inability to secure a partner for ICT-107; the risk that
future trials of ICT-107, if any, do not confirm the safety and
efficacy data generated in the Phase I trial; the need to
satisfy performance milestones to maintain the vaccine technology
licenses with Cedars-Sinai; the risks associated with obtaining a
patent that provides commercially significant protection for
ICT-107; and the need for substantial additional capital to fund
development of product candidates beyond their initial clinical or
pre-clinical stages and to continue IMUC's operations. Additional
risks and uncertainties are described in IMUC's most recently filed
SEC documents, such as its most recent annual report on Form 10-K,
all quarterly reports on Form 10-Q and any current reports on Form
8-K. IMUC undertakes no obligation to publicly update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise.

Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment.